Becton, Dickinson and Company $BDX Shares Purchased by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System boosted its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 27.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,737 shares of the medical instruments supplier’s stock after buying an additional 4,264 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Becton, Dickinson and Company were worth $3,533,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. TD Waterhouse Canada Inc. raised its position in shares of Becton, Dickinson and Company by 17.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock valued at $14,715,000 after acquiring an additional 14,077 shares in the last quarter. Northside Capital Management LLC boosted its holdings in Becton, Dickinson and Company by 18.3% in the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after purchasing an additional 9,494 shares during the period. Capital Analysts LLC boosted its holdings in Becton, Dickinson and Company by 7.5% in the second quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier’s stock worth $12,651,000 after purchasing an additional 5,828 shares during the period. NewEdge Advisors LLC increased its stake in Becton, Dickinson and Company by 35.0% during the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after purchasing an additional 11,414 shares during the last quarter. Finally, Beverly Hills Private Wealth LLC bought a new stake in Becton, Dickinson and Company during the second quarter valued at $3,353,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,993 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $210.00, for a total transaction of $628,530.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $23,134,230. This represents a 2.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 3,310 shares of company stock valued at $688,650. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0%

Shares of NYSE BDX opened at $217.95 on Monday. Becton, Dickinson and Company has a 12-month low of $140.11 and a 12-month high of $219.78. The company has a market cap of $60.05 billion, a price-to-earnings ratio of 52.64, a price-to-earnings-growth ratio of 3.65 and a beta of 0.22. The company has a current ratio of 0.87, a quick ratio of 0.54 and a debt-to-equity ratio of 0.54. The stock’s 50 day simple moving average is $190.90 and its 200 day simple moving average is $170.56.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.11 billion. During the same period in the prior year, the business earned $3.96 EPS. The firm’s revenue was up 5.4% on a year-over-year basis. Equities research analysts expect that Becton, Dickinson and Company will post 13.21 EPS for the current year.

Becton, Dickinson and Company declared that its board has approved a stock repurchase program on Thursday, November 5th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 3.6% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be issued a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 1.9%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date of this dividend is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 101.45%.

Wall Street Analyst Weigh In

BDX has been the topic of a number of research reports. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. Zacks Research raised shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 21st. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Royal Bank Of Canada boosted their price objective on shares of Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research report on Friday, November 6th. Finally, Bank of America increased their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $197.47.

Read Our Latest Stock Analysis on BDX

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.